Hepatotoxicity CML Chronic Myeloid Leukemia
ARTICLES
BMS Warns of Liver Damage from Sprycel
February 22, 2023, Formulary Watch
New-Generation BCR-ABL TKIs Linked to Increased Risk of Hepatotoxicity in Patients With Chronic Myeloid Leukemia
August 4, 2021, Oncology Nurse Advisor
Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
June 14, 2019, Clinical case reports
Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity
April 2019, Hong Kong Medical Journal
CML: Managing TKI-Related Toxicity To Yield the Best Outcomes
March 12, 2018, Cancer Therapy Advisor
Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
November 15, 2014, PubMed
Ponatinib and hepatotoxicity
July 25, 2014, Livertox
Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
January 2014, PubMed
Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone
February 23, 2011, BMJ Case Reports
Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study
November 15, 2009, PubMed
Corticosteroids can reverse severe imatinib-induced hepatotoxicity
2006, Haematologica
BMS Warns of Liver Damage from Sprycel
February 22, 2023, Formulary Watch
New-Generation BCR-ABL TKIs Linked to Increased Risk of Hepatotoxicity in Patients With Chronic Myeloid Leukemia
August 4, 2021, Oncology Nurse Advisor
Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
June 14, 2019, Clinical case reports
Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity
April 2019, Hong Kong Medical Journal
CML: Managing TKI-Related Toxicity To Yield the Best Outcomes
March 12, 2018, Cancer Therapy Advisor
Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
November 15, 2014, PubMed
Ponatinib and hepatotoxicity
July 25, 2014, Livertox
Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity
January 2014, PubMed
Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone
February 23, 2011, BMJ Case Reports
Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study
November 15, 2009, PubMed
Corticosteroids can reverse severe imatinib-induced hepatotoxicity
2006, Haematologica
